Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-0524B combination tablet versus MK-0524A + simvastatin in primary hypercholesterolemia and mixed dyslipidemia
2007-002516-26Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Niacin + laropiprant + simvastatin, laropiprant + niacin and simvastatin in hypercholesterolemia and combined dyslipidaemia (2 arms), sponsored by Merck & Co. Primary endpoint: Change in LDL-C from baseline. Started Jun 2007; status: completed.
02
Drugs
Niacin + laropiprant + simvastatinlaropiprant + niacinsimvastatin
03
Conditions
hypercholesterolemiacombined dyslipidaemia
Beyond the preview
Go deeper on 2007-002516-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002516-26.